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In 2016, just over 2 million people worldwide acquired HIV infection, mostly via heterosexual
transmission and mostly in sub-Saharan Africa [1]. Antiretroviral treatment (ART) aims to
suppress viral load to very low, or undetectable, levels, delaying HIV disease progression [2,3]
and reducing the risk of onward transmission [4]. Following the 2015 WHO guidelines recom-
mending ART for all HIV-positive people regardless of CD4 count, WHO and the Joint
United Nations Programme on HIV/AIDS (UNAIDS) issued the 90–90–90 target, aiming by
2020 to have 90% of infected people knowing their HIV status, 90% of HIV-positive people ini-
tiated on ART, and 90% of people treated with ART virally suppressed [5], so as to achieve
containment of the HIV epidemic.
We commend Richard Hayes and colleagues for their success in navigating the complex logis-
tic challenges in implementing a large-scale universal testing and treatment (UTT) intervention
in sub-Saharan Africa, as described in their accompanying research article in PLOS Medicine [6].
They report how close they were able to come to reaching the first two stages of the 90–90–90
target in four communities in Zambia after one year of implementing their PopART interven-
tion (comprising home-based HIV testing by Community HIV care Providers [CHiPs] with
support for linkage to care, adherence, and retention). Among those consenting to the interven-
tion, 6,197 HIV-positive individuals not on ART (most of whom had never been in care) were
referred to care, 42% of whom initiated ART within six months and 53% by 12 months. Extrapo-
lating to the entire population, the estimated percentage of HIV-positive adults who knew their
status increased from 52% to 78% (men) and from 56% to 87% (women); percentages of known
HIV-positive people on ART increased from 54% to 74% (men) and from 53% to 73% (women).
The overall estimated percentage of HIV-positive adults on ART was 61% after 1 y of interven-
tion implementation, compared to the WHO/UNAIDS target of 81% (90% of 90%). We note
that many process indicators in the study were based on self-report and, apparently, data from
the CHiPs electronic capture system were not verified with clinic data. Further, in this setting, in
which nearly 50% of all HIV-positive individuals were ART-naive because they were newly diag-
nosed, it is likely that most of the 20% of people who migrated out of the area never linked to
care or commenced ART. This 20% of people, no longer resident in the PopART communities,
was not included in the denominator for the post-CHiPs evaluation at 12 months on linkage to
care and ART initiation, which could have resulted in an overestimate of the change observed
following the CHiPs intervention.
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Hayes and colleagues’ findings thus confirm the high acceptability of home-based HIV test-
ing, and a less-than-optimal linkage to care, with initiation of ART rates suggesting that those
who do link to care are willing to start ART; there is a substantial proportion of people identi-
fied as HIV positive who do not (yet) link to care, can therefore not be initiated on ART, and
who may continue to transmit HIV. The Agence Nationale de Recherche sur le Sida et les
he´patites virales (ANRS) 12249 Treatment as Prevention (TasP) trial, also evaluating a UTT
intervention in rural South Africa, recently reported that 92% of HIV-positive individuals
knew their status, 49% of those people initiated ART, and 93% achieved virological suppres-
sion on ART [7]. Higher rates of ART initiation were reported from Uganda and Kenya in the
Sustainable East Africa Research in Community Health (SEARCH) trial, another UTT inter-
vention study, with 97% of HIV-positive individuals knowing their status, 93% on ART, and
90% virologically suppressed at the end of year two [8]. Similarly, estimates from the Botswana
Combination Prevention Project (BCPP) trial, a UTT intervention implemented in Botswana,
reported that, overall, 70% of all HIV-positive individuals were virologically suppressed, close
to the UNAIDS target of 73% (90% of 90% of 90%), with 83% of HIV-positive individuals diag-
nosed and 87% on ART, of whom 97% achieved virological suppression [9]. The different
approaches to the estimation of percentages in the HIV care cascade in these trials hinder
direct comparison of results; hence, we agree with Hayes and colleagues that approaches for
estimating proportions of people at different stages in the HIV cascade need to be harmonised.
Hayes and colleagues report that it was challenging to find young men at home, again in
line with experience elsewhere [10]. Slow linkage to care suggests that people will only attend
facilities once they prioritise doing so, and this is especially pertinent before they are driven to
do so by the development of HIV symptoms and signs. An earlier study in rural KwaZulu-
Natal highlighted that linkage to care was significantly less likely in those who had never been
in HIV care, students in education, and those further away from the clinic, while those who
had positive experience of ART in friends or family were more likely to access the trial clinic
[11]. Hayes and colleagues will address progress towards the third 90% target later in their
trial, but evidence from other studies suggests that once people engage with ART care, they are
likely to adhere, at least in the short term [7], and that early linkage to ART care is the main
hurdle in the HIV care cascade.
The big question remains whether, in the global heterosexually-driven HIV epidemic, UTT
will ultimately reduce HIV incidence to levels sufficient for containment. Findings from the
ANRS 12249 TasP trial in South Africa showed little impact on HIV incidence [7], likely due
to the slow linkage to care. Hayes and colleagues, although suggesting success of UTT in the
first round of trial implementation, do not provide information about sustainability of either
HIV test offer uptake or ART adherence, issues which may be especially important in settings
with high migration movements.
Overall, these results would suggest that it is unlikely that the rather optimistic forecasts,
based on statistical modelling [12], of an imminent end to the global HIV epidemic will be
fulfilled. The current gloomy political environment, with uncertainty about the global will to
continue to support the large-scale implementation of HIV treatment and care programmes
worldwide [13], further adds to the already considerable challenges faced by public health
programmes in many settings with a high HIV burden. Health care system requirements for a
successful UTT programme are not negligible, even if a UTT approach is found to be cost-
effective [14]. Substantial resources are needed to further scale up ART for all HIV-positive
adults, and allocation of limited resources will need to be optimised on the basis of evidence of
efficacy. Given extensive resource constraints, there may come a time to consider whether
public programmes will need to focus on providing optimal health care and support for those
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people who engage with care at public facilities and who have thus indicated that they have
prioritised access to health care in their lives.
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